Skip to main content
Top
Published in: CEN Case Reports 1/2021

01-02-2021 | Venous Thrombosis | Case Report

Difficulty in managing nephrotic syndrome-associated cerebral venous thrombosis

Authors: Takashin Nakayama, Ryunosuke Mitsuno, Takuto Torimitsu, Norifumi Yoshimoto, Takeshi Kanda, Hirobumi Tokuyama, Shu Wakino, Hiroshi Itoh

Published in: CEN Case Reports | Issue 1/2021

Login to get access

Abstract

Thromboembolism is one of the most serious complications of nephrotic syndrome (NS). Although the occurrence of renal vein thrombosis or deep vein thrombosis is well recognized in NS patients, they rarely develop cerebral venous thrombosis (CVT). The mortality rate of CVT patients is still approximately 10%, and 6–10% of patients who survive have a severe and permanent disability. Herein, we report the case of a 26-year-old woman with multiple thrombotic risk factors, including the presence of NS, use of oral contraceptives, smoking, and alcohol consumption who developed wide-range CVT. Undetermined fraction heparin, albumin and AT-III transfusion, and direct mechanical catheter thrombectomy were insufficient for the improvement of CVT. However, CVT eventually improved along with the remission of NS by prednisolone administration. This process indicates that in the management of CVT associated with NS, it is crucial to control the activity of NS. Currently, knowledge on the treatment for NS associated with CVT is limited, and this is a subject of urgent investigation.
Literature
1.
go back to reference Stam J. Thrombosis of the cerebral veins and sinuses. N Engl J Med. 2005;352(17):1791–8.CrossRef Stam J. Thrombosis of the cerebral veins and sinuses. N Engl J Med. 2005;352(17):1791–8.CrossRef
2.
go back to reference Ferro JM, Canhão P, Stam J, et al. Barinagarrementeria F. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke. 2004;35(3):664–70.CrossRef Ferro JM, Canhão P, Stam J, et al. Barinagarrementeria F. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke. 2004;35(3):664–70.CrossRef
3.
go back to reference Silvis SM, de Sousa DA, Ferro JM, et al. Cerebral venous thrombosis. Nat Rev Neurol. 2017;13(9):555–65.CrossRef Silvis SM, de Sousa DA, Ferro JM, et al. Cerebral venous thrombosis. Nat Rev Neurol. 2017;13(9):555–65.CrossRef
4.
go back to reference Green M, Styles T, Russell T, et al. Non-genetic and genetic risk factors for adult cerebral venous thrombosis. Thromb Res. 2018;169:15–22.CrossRef Green M, Styles T, Russell T, et al. Non-genetic and genetic risk factors for adult cerebral venous thrombosis. Thromb Res. 2018;169:15–22.CrossRef
5.
go back to reference Dentali F, Gianni M, Crowther MA, et al. Natural history of cerebral vein thrombosis: a systematic review. Blood. 2006;108(4):1129–34.CrossRef Dentali F, Gianni M, Crowther MA, et al. Natural history of cerebral vein thrombosis: a systematic review. Blood. 2006;108(4):1129–34.CrossRef
6.
go back to reference Coutinho JM, Zuurbier SM, Stam J. Declining mortality in cerebral venous thrombosis: a systematic review. Stroke. 2014;45(5):1338–411.CrossRef Coutinho JM, Zuurbier SM, Stam J. Declining mortality in cerebral venous thrombosis: a systematic review. Stroke. 2014;45(5):1338–411.CrossRef
7.
go back to reference Kerlin BA, Ayoob R, Smoyer WE. Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease. Clin J Am Soc Nephrol. 2012;7(3):513–20.CrossRef Kerlin BA, Ayoob R, Smoyer WE. Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease. Clin J Am Soc Nephrol. 2012;7(3):513–20.CrossRef
8.
go back to reference Al Azzawi HF, Obi OC, Safi J, et al. Nephrotic syndrome-induced thromboembolism in adults. Int J Crit Illn Inj Sci. 2016;6(2):85–8.CrossRef Al Azzawi HF, Obi OC, Safi J, et al. Nephrotic syndrome-induced thromboembolism in adults. Int J Crit Illn Inj Sci. 2016;6(2):85–8.CrossRef
9.
go back to reference Bakhtawar K, Mahmoodi B. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study. Circulation. 2008;117(2):224–30.CrossRef Bakhtawar K, Mahmoodi B. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study. Circulation. 2008;117(2):224–30.CrossRef
10.
go back to reference Cameron JS, Blandford G. The simple assessment of selectivity in heavy proteinuria. Lancet. 1966;30(2):242–7.CrossRef Cameron JS, Blandford G. The simple assessment of selectivity in heavy proteinuria. Lancet. 1966;30(2):242–7.CrossRef
11.
go back to reference Iwaki H, Neshige S, Hara N, et al. Cerebral venous thrombosis as a complication of nephrotic syndrome–a case report and literature review. Rinsho Shinkeigaku. 2014;54(6):495–501 (in Japanese).CrossRef Iwaki H, Neshige S, Hara N, et al. Cerebral venous thrombosis as a complication of nephrotic syndrome–a case report and literature review. Rinsho Shinkeigaku. 2014;54(6):495–501 (in Japanese).CrossRef
12.
go back to reference Zhang LJ, Zhang Z, Li SJ, et al. Pulmonary embolism and renal vein thrombosis in patients with nephrotic syndrome: prospective evaluation of prevalence and risk factors with CT. Radiology. 2014;273(3):897–906.CrossRef Zhang LJ, Zhang Z, Li SJ, et al. Pulmonary embolism and renal vein thrombosis in patients with nephrotic syndrome: prospective evaluation of prevalence and risk factors with CT. Radiology. 2014;273(3):897–906.CrossRef
13.
go back to reference Johannesdottir SA, Horváth-Puhó E, Dekkers OM, et al. Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. JAMA Intern Med. 2013;173(9):743–52.CrossRef Johannesdottir SA, Horváth-Puhó E, Dekkers OM, et al. Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. JAMA Intern Med. 2013;173(9):743–52.CrossRef
14.
go back to reference Zaffanello M, Brugnara M, Fanos V, et al. Prophylaxis with AT III for thromboembolism in nephrotic syndrome: why should it be done? Int Urol and Nephrol. 2009;41(3):713–6.CrossRef Zaffanello M, Brugnara M, Fanos V, et al. Prophylaxis with AT III for thromboembolism in nephrotic syndrome: why should it be done? Int Urol and Nephrol. 2009;41(3):713–6.CrossRef
15.
go back to reference Nishi S, Ubara Y, Utsunomiya Y, et al. Evidence-based clinical practice guidelines for nephrotic syndrome. Clin Exp Nephrol. 2014;20(3):342–70.CrossRef Nishi S, Ubara Y, Utsunomiya Y, et al. Evidence-based clinical practice guidelines for nephrotic syndrome. Clin Exp Nephrol. 2014;20(3):342–70.CrossRef
16.
go back to reference Radhakrishnan J, Cattran DC. The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines—application to the individual patient. Kidney Int. 2012;82(8):840–56.CrossRef Radhakrishnan J, Cattran DC. The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines—application to the individual patient. Kidney Int. 2012;82(8):840–56.CrossRef
17.
go back to reference Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis. 2018;77(6):808–18.PubMed Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis. 2018;77(6):808–18.PubMed
18.
go back to reference Saposnik G, Barinagarrementeria F, Brown RD, et al. American Heart Association Stroke Council and the Council on Epidemiology and Prevention Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(4):1158–92.CrossRef Saposnik G, Barinagarrementeria F, Brown RD, et al. American Heart Association Stroke Council and the Council on Epidemiology and Prevention Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(4):1158–92.CrossRef
19.
go back to reference Einhäupl K, Stam J, Bousser MG, et al. European Federation of Neurological Societies. EFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients. Eur J Neurol. 2010;17(10):1229–355.CrossRef Einhäupl K, Stam J, Bousser MG, et al. European Federation of Neurological Societies. EFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients. Eur J Neurol. 2010;17(10):1229–355.CrossRef
20.
go back to reference Shinohara Y, Yamaguchi T. Outline of the Japanese guidelines for the management of stroke 2004 and subsequent revision. Int J Stroke. 2007;2:133–5.CrossRef Shinohara Y, Yamaguchi T. Outline of the Japanese guidelines for the management of stroke 2004 and subsequent revision. Int J Stroke. 2007;2:133–5.CrossRef
21.
go back to reference van Dongen CJ, van den Belt AG, Prins M, et al. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev. 2004;4:CD001100. van Dongen CJ, van den Belt AG, Prins M, et al. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev. 2004;4:CD001100.
22.
go back to reference Vaziri ND, Paule P, Toohey J, et al. Acquired deficiency and urinary excretion of antithrombin III in nephrotic syndrome. Arch Intern Med. 1984;144(9):1802–3.CrossRef Vaziri ND, Paule P, Toohey J, et al. Acquired deficiency and urinary excretion of antithrombin III in nephrotic syndrome. Arch Intern Med. 1984;144(9):1802–3.CrossRef
23.
go back to reference Li SJ, Tu YM, Zhou CS, et al. Risk factors of venous thromboembolism in focal segmental glomerulosclerosis with nephrotic syndrome. Clin Exp Nephrol. 2016;20(2):212–7.CrossRef Li SJ, Tu YM, Zhou CS, et al. Risk factors of venous thromboembolism in focal segmental glomerulosclerosis with nephrotic syndrome. Clin Exp Nephrol. 2016;20(2):212–7.CrossRef
24.
go back to reference Robert A, Olmer M, Sampol J, et al. Clinical correlation between hypercoagulability and thrombo-embolic phenomena. Kidney Int. 1978;31(3):830–5.CrossRef Robert A, Olmer M, Sampol J, et al. Clinical correlation between hypercoagulability and thrombo-embolic phenomena. Kidney Int. 1978;31(3):830–5.CrossRef
25.
go back to reference Cherng SC, Huang WS, Wang YF, et al. The role of lung scintigraphy in the diagnosis of nephrotic syndrome with pulmonary embolism. Clin Nucl Med. 2000;25:167–72.CrossRef Cherng SC, Huang WS, Wang YF, et al. The role of lung scintigraphy in the diagnosis of nephrotic syndrome with pulmonary embolism. Clin Nucl Med. 2000;25:167–72.CrossRef
Metadata
Title
Difficulty in managing nephrotic syndrome-associated cerebral venous thrombosis
Authors
Takashin Nakayama
Ryunosuke Mitsuno
Takuto Torimitsu
Norifumi Yoshimoto
Takeshi Kanda
Hirobumi Tokuyama
Shu Wakino
Hiroshi Itoh
Publication date
01-02-2021
Publisher
Springer Singapore
Published in
CEN Case Reports / Issue 1/2021
Electronic ISSN: 2192-4449
DOI
https://doi.org/10.1007/s13730-020-00520-7

Other articles of this Issue 1/2021

CEN Case Reports 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.